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Amino acids are fundamental building blocks supporting life. Their role in protein synthesis is well defined,
but they contribute to a host of other intracellular metabolic pathways, including ATP generation, nucleotide
synthesis, and redox balance, to support cellular and organismal function. Immune cells critically depend on
such pathways to acquire energy and biomass and to reprogram their metabolism upon activation to support
growth, proliferation, and effector functions. Amino acid metabolism plays a key role in this metabolic rewir-
ing, and it supports various immune cell functions beyond increased protein synthesis. Here, we review the
mechanisms by which amino acid metabolism promotes immune cell function, and how these processes
could be targeted to improve immunity in pathological conditions.Introduction
Amino acids are fundamental units that supported the earliest life
on earth. Individual amino acids can be created abiotically and
have been detected in extraterrestrial sources such as meteor-
ites (Burton et al., 2012). Amajor evolutionary stepwas the ability
to combine amino acids into peptides and then proteins, which
mediate cellular functions. In addition to protein synthesis, amino
acids are used for many other processes driving growth and pro-
liferation. Amino acid metabolism has profound consequences
for cell function, not the least of which include that of immune
cells, which are critically dependent on metabolic status due to
their dynamic activation states as they respond to infections
and changes in their tissue environments (Buck et al., 2017).
Amino acids are a key nutrient for immune cells, and amino
acid supply instructs immune cell function. Immune cells have
specific amino acid requirements, while growth factor stimula-
tion and activation of T cells, which induce their rapid prolifera-
tion, increase amino acid transporter expression (Geiger et al.,
2016; Ron-Harel et al., 2019; Sinclair et al., 2019), illustrating
the need for enhanced amino acid uptake during this process.
Upon activation, T cells rapidly proliferate and undergo
increased gene transcription-translation for critical immune-
related responses, such as cytokines and adhesion molecules,
and thus must upregulate protein synthesis. Such responses
are metabolically demanding, as new DNA, proteins, nucleo-
tides, and other biomolecules must be produced before cells
can divide and mount an immune response. However, it is now
appreciated that amino acids have multiple signaling roles and
supply material for more than just energy and protein synthesis.
In this review, we explore how amino acids go beyond merely
supporting protein synthesis to control immune cell function. We
examine how different immune cells selectively acquire amino
acids, rather than their indiscriminate uptake, downstream of an-
tigen and cytokine signaling and the control of amino acid trans-
porter expression.We then discuss how amino acids support the
metabolic reprogramming critical for immune cell activation. In
addition, we expand on the idea that amino acids are not just
used for the end result of this reprogramming, i.e., increased
biosynthesis to drive proliferation and effector molecule produc-
tion. Instead, they control these metabolic switches by feedingdifferent ATP-producing pathways, such as glycolysis and mito-
chondrial metabolism, via the tricarboxylic acid (TCA) cycle and
oxidative phosphorylation (OXPHOS). And as reactive oxygen
species (ROS) production is a key step in immune cell activation,
we describe how amino acids are central regulators of redox bal-
ance within immune cells, and how sulfur supply from cysteine
andmethioninemay determine continuedmetabolic and transla-
tional activity in cells with altered redox status. Further, we re-
view how amino acids tune immune effector protein activity by
supplying intermediates, such as methyl and acetyl groups, for
post-translational modification (PTM), and how such intermedi-
ates also epigenetically regulate acute immune responses and
immune cell memory. Finally, we investigate amino acid compe-
tition between immune and tumor cells, and explore how target-
ing amino acid metabolism could modulate immune responses
in cancer, infection, and autoimmunity.
Acquisition and Sensing of Amino Acids
An amino acid is an organic molecule containing an amino group
and a carboxyl group attached to a carbon atom. Each amino
acid also has a unique side chain, which bestows different prop-
erties and functions (Wu, 2009). A limited set of 10 amino acids,
produced by abiotic chemical or physical reactions, may have
been used for very early proteinogenesis before cellular biosyn-
thesis evolved (Frenkel-Pinter et al., 2019; Longo and Blaber,
2012). A consensus set of these 10 early amino acids comprises
alanine, aspartate, glutamate, glycine, isoleucine, leucine, pro-
line, serine, threonine, and valine (Doi et al., 2005b), while the
more complex aromatic amino acids tryptophan and phenylala-
nine, and the sulfurous amino acid methionine, arose later
(Longo et al., 2015). Mammals use a set of 20 amino acids for
protein synthesis, though many more exist in nature and influ-
ence cell function (Schuller-Levis and Park, 2003). Nine of these
20 proteinogenic amino acids are known as essential amino
acids, as they cannot be sufficiently synthesized by the body
and must be acquired from dietary sources (Wu, 2013). In
contrast, non-essential amino acids can be synthesized to suffi-
cient levels in the body and do not need to be acquired, but can
become conditionally essential under conditions in which de-
mand exceeds the body’s capacity for synthesizing themCell Metabolism 32, August 4, 2020 ª 2020 Elsevier Inc. 1
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curs in rapidly proliferating cells (Curthoys and Watford, 1995),
which need amino acids for protein synthesis and increased
biomass (Hosios et al., 2016). Given the marked changes in
cell growth and proliferation that are characteristic of immune
cells responding to alterations in their extracellular environment,
it is likely that for these cells non-essential amino acids may
become conditionally essential during an immune response.
Acquisition of Amino Acids
Amino acid acquisition is a point of control for cell function. Up-
take from the external environment relies on transporters, while
intracellularly, amino acids are recycled and donate functional
groups for other amino acids. For example, glutamine supplies
amino groups for other amino acids via transamination and
transamidation, and methionine is metabolized to cysteine in
the methionine cycle (Sinclair et al., 2019). Lysosomes also
contain amino acid transport machinery (Sagne´ et al., 2001;
Wyant et al., 2017), and can act as intracellular amino acid de-
pots (Abu-Remaileh et al., 2017), important for cell function.
For example, the lysosomal histidine transporter Slc15a4 is
needed for Toll-like receptor (TLR)-induced type I interferon
(IFN-I) production in plasmacytoid dendritic cells (pDCs), and
IFN-I and immunoglobulin (Ig)G production in B cells (Kobayashi
et al., 2014). During starvation, amino acids are sequestered in
the lysosome, possibly to prevent their inappropriate use during
this nutrient-restricted period. One possible consequence of
such lysosomal amino acid storage is induction of autophagy,
which promotes longevity, in part by antagonizing the age-
related decline in CD8+ T cell function and immune responses
to infection and cancer (Pietrocola et al., 2016; Puleston et al.,
2014). Lysosomal storage could also provide the cell with a
bank of amino acids that can be mobilized when protein synthe-
sis resumes, and autophagy would presumably increase amino
acid availability in this context. Amino acids could be selectively
released to drive particular gene expression programs to adapt
to prolonged starvation or nutrient restoration; for example, by
influencing epigenetic modifications.
Amino Acid Transporters Control Immune Cell Function
Amino acid uptake via transporters is a tightly regulated process
that is critical for immune cell activation and function. A compre-
hensive proteomic analysis of human immune cells illustrated the
vast diversity of transporters and receptors expressed by
different immune cell types, and how these transporters change
expression upon antigen stimulation and cytokine signaling
(Rieckmann et al., 2017). This has been more specifically
explored in a proteomic analysis of CD4+ and CD8+ T cells,
which illustrated how antigen and cytokine stimulation changes
expression of amino acid transporters to alter nutrient uptake
and specifically enable effector function in activated T cells
(Howden et al., 2019). Activation of CD8+ T cells by T cell recep-
tor (TCR) stimulation in the presence of growth factor cytokines,
e.g., interleukin (IL)-2, increases the density of Slc1a5 and
Slc7a5 on the cell surface compared to naive CD8+ T cells. Acti-
vated T cells require a supply of amino acids to support prolifer-
ation, and this activation-dependent enhancement of transporter
expression ensures that cells can acquire these nutrients ac-
cording to their demand. It is not only the type, but the level of
transporter expression, that influences T cell function.While acti-
vated CD4+ and CD8+ T cells express a similar nutrient trans-2 Cell Metabolism 32, August 4, 2020porter repertoire, CD4+ T cells have a lower copy number of
these transporters and less nutrient transport (Howden et al.,
2019; Sinclair et al., 2013; Swamy et al., 2016). This difference,
in combination with the lower levels of ribosomes and transla-
tional machinery in activated CD4+ versus CD8+ T cells, could
underlie the lower cell mass and proliferative capacity of acti-
vated CD4+ T cells compared to CD8+ T cells. Such a detailed
study of changes in amino acid transporter expression in other
immune cell types would be highly informative, as their activation
also depends on amino acid transporter activity. Further, both
classical and alternative macrophage activation depend on argi-
nine uptake via cationic amino acid transporter (CAT)2 (Slc7a2)
(Yeramian et al., 2006b), while resting macrophages use the
y+L (Slc7a6, Slc7a7) system for arginine uptake, likely via CAT1
(Slc7a1) (Yeramian et al., 2006a). Lipopolysaccharide (LPS) in-
creases Slc7a5 expression and leucine uptake to support human
pro-inflammatory macrophage cytokine production (Yoon et al.,
2018). These examples illustrate how innate immune cell activa-
tion depends on remodeling of amino acid transporter activity.
Multiple signaling pathways in turn control transporter expres-
sion. Myc, a central transcription factor driving T cell activation,
increases Slc1a5, Slc7a1, Slc7a5, Slc38a1, and Slc38a2 on acti-
vated CD4+ and CD8+ T cells (Marchingo et al., 2020). Myc defi-
ciency blocks activated T cell growth by reducing expression of
these transporters to that of naive cells. TCR stimulation also
activates the mitogen-activated protein kinase (MAPK) family
member extracellular signal-regulated kinase (ERK) to increase
glutamine uptake (Carr et al., 2010), possibly by increasing surface
sodium-coupled neutral amino acid transporter (SNAT)2 (Slc38a2)
expression (Franchi-Gazzola et al., 1999). Multiple pathways con-
trol expression of individual transporters. Slc7a5 expression also
depends on calcium-calcineurin signaling (Sinclair et al., 2013),
and both ERK and c-Jun N-terminal kinase (JNK) control SNAT2
(Hyde et al., 2007). Differential regulation of transporters and use
of signaling pathways underlie the varying effects of cytokines
on T cell growth and proliferation. IL-2 and IL-15 both signal
through CD122 and activate Janus kinase (JAK)1, JAK3, and
signal transducer and activator of transcription (STAT)5, but with
different consequences for antigen-activated T cells. IL-2 pro-
motes CD8+ effector T (Teff) cell formation and cell growth, while
IL-15 is needed for the formation of CD8+ memory T (Tmem) cells,
which are smaller in size. T cells maintained in IL-2 have higher
CD98 (Slc7a5/Slc3a2) expression than those in IL-15, and in-
crease amino acid uptake and protein synthesis, underlying the
different effects of these cytokines on T cell growth (Cornish
et al., 2006). These effects depend on sustained phosphoinosi-
tide-3-kinase (PI3K) signaling in T cells cultured in IL-2 versus
more transient PI3K signaling in IL-15-cultured cells. More work
is needed to understand how divergent effects of cytokines on
signaling pathway activities and kinetics control immune cell
growth via modulation of amino acid transporters.
Asymmetric Distribution of Amino Acid Transporters
Influences T Cell Fate
During an infection, a T cell population must generate Teff cells to
fight the infection, as well as Tmem cells to provide long-lasting
immunity. Asymmetric cell division, in which the two daughter
cells generated by a cell division event adopt different fates, is
one model proposed for T cells to achieve this goal (Arsenio
et al., 2014, 2015; Reiner and Adams, 2014). In asymmetric cell
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Antigen presentation by antigen-presenting cells (APCs) stimu-
lates activation and proliferation of naive T cells. The T cell prox-
imal to the APC adopts an effector-like fate, while the distal T cell
assumes a memory-like fate, based on the asymmetric inheri-
tance of factors, including CD3, CD4, CD8, CD62L, transcription
factors, and mechanistic target of rapamycin (mTOR), between
the daughter cells (Chang et al., 2007). Slc1a5 is one such asym-
metrically inherited factor. Slc1a5 preferentially accumulates in
the proximal cell, which also exhibits increased amino acid abun-
dance, glutamine uptake, glycolysis, c-Myc, andmTOR complex
(mTORC)1 activity (Verbist et al., 2016). The direct effect of
Slc1a5 on c-Myc levels was not established in this system, but
amino acid deprivation or blockade of glutaminolysis reduces
the differences in c-Myc between the daughter cells, and
reducing c-Myc levels pushes the daughter cells toward a mem-
ory-like phenotype (Verbist et al., 2016). This study established
that metabolic asymmetry, specifically in terms of amino acid
acquisition, may underlie different T cell fates. Similarly,
daughter CD8+ T cells with increased Slc7a5 expression have
increased CD8 expression, mTORC1 activity, Myc levels, and
glycolysis, while cells with lower CD8 and Slc7a5 expression
have increased mitochondrial mass. Slc7a5 inhibition, but not
mTORC1 inhibition, decreases mTORC1 lysosomal transloca-
tion in CD8hi daughter cells, indicating amino acid supply
through Slc7a5 as an upstream regulator of the asymmetric
division ofmTORC1 activity (Pollizzi et al., 2016). Together, these
results implicate amino acid metabolism and cellular metabolic
profiles as determinants of cell fate.
Sensing Amino Acid Supply
Multiple mechanisms sense amino acids to control immune cell
metabolism.mTORC1 is a central cellular signaling hub that drives
protein synthesis, cell growth, and proliferation, while the general
controlled non-repressed kinase 2 (GCN2) senses amino acid
starvation by detecting uncharged tRNA. The precise mecha-
nisms of amino acid sensing by thesemolecules have been exten-
sively reviewed elsewhere (Bar-Peled et al., 2013; Kedersha et al.,
2002; Saxton and Sabatini, 2017; Taniuchi et al., 2016). mTORC1
licenses immune cell activation only when enough resources are
present. Active mTORC1 promotes the differentiation of CD8+
cytotoxic T cells (CTLs) (Pollizzi et al., 2015; Rao et al., 2010), con-
trols Tmem cell formation (Araki et al., 2009a; Pearce et al., 2009),
and stimulates helper T (Th)1 and Th17 differentiation while re-
straining regulatory T (Treg) generation (Delgoffe et al., 2011). In
macrophages, pharmacologically activating GCN2 and the amino
acid starvation response dampens IL-1b production (Battu et al.,
2018), and inhibits inflammasome-mediated gut inflammation
(Ravindran et al., 2016). Upon activation, both innate and adaptive
immune cells must sense their amino acid supplies in order to
engage the new biosynthetic programs that accompany this acti-
vation, and mTORC1 and GCN2 are central regulators of amino
acid usage in this context.
Amino Acids Support Immune Cell Metabolic
Reprogramming
Immune cell activation by receptor ligation and cytokine
signaling induces drastic changes in transcription and transla-
tion, for cytokine and effector molecule production, as well asextensive proliferation, which requires acquisition of biomass
for cell division. Immune cells reprogram their metabolism to
support these exceptionally high metabolic demands. Distinct
metabolic pathways fuel different immune cells, and metabolic
reprogramming dictates immune cell survival, differentiation,
and function (Geltink et al., 2018; O’Neill et al., 2016).
A major requirement of activated immune cells is energy in the
form of ATP. Glycolysis, the TCA cycle, and OXPHOS cooperate
to produce ATP, and amino acids regulate these interconnected
processes. Glycolysis processes glucose to pyruvate, gener-
ating ATP and NADH, a cofactor for a multitude of enzymes,
including those of mitochondrial metabolism. Pyruvate-derived
acetyl-CoA enters the TCA cycle in the mitochondria to generate
the reducing equivalents NADH and FADH2 that provide elec-
trons for OXPHOS. Mitochondrial fatty acid oxidation (FAO)
yields acetyl-CoA, NADH, and FADH2, further driving mitochon-
drial metabolism and ATP production. Amino acid metabolism
contributes to these pathways (Figure 1), the differential use of
which dictates immune cell function (Box 1).
Glutamine Supports Metabolic Rewiring
Glutamine provides intermediates for many metabolic pathways.
Glutaminolysis is a major energy-producing process for prolifer-
ating cells, including activated T cells (Newsholme et al., 1999),
by supplying a-ketoglutarate (aKG) to the TCA cycle, via gluta-
mate. Glutamine is required for T cell activation (Yaqoob and
Calder, 1997), as T cells cultured without glutamine cannot
proliferate or produce IL-2 or IFN-g (Carr et al., 2010). Supplemen-
tationwith asparagine, proline, or glutamate,which can bemetab-
olized to glutamine, does not recue proliferation or cytokine de-
fects due to glutamine withdrawal, indicating that acquisition of
extracellular glutamine, and not its intracellular generation, is the
key regulatory event. This explains why naive T cell activation in-
duces glutamine uptake, dependent on SNAT1, SNAT2 (Slc38a2)
(Carr et al., 2010) and the alanine, serine, cysteine-preferring
transporter 2 (ASCT2; Slc1a5) (Nakaya et al., 2014). ASCT2
disruption inhibits Th1 and Th17 differentiation, though prolifera-
tion and IL-2 production are normal (Nakaya et al., 2014). The
increased glycolysis and mitochondrial metabolism necessary to
support T cell differentiation is also impaired in Asct2/ CD4+
T cells, as they have decreased glucose uptake, lactate produc-
tion, and oxygen consumption. Glutamine addition rescues these
effects, though other amino acids transported by ASCT2 could
theoretically also contribute to the phenotype.
While glutamine supports both Th1 and Th17 cell differentia-
tion, glutamine degradation by glutaminolysis may be more crit-
ical specifically for Th17 cells, while other downstream effects of
glutamine may influence Th1 cell differentiation (Johnson et al.,
2018). This is illustrated in mice lacking glutaminase 1 (Gls1)
(Kono et al., 2018), which metabolizes glutamine to glutamate.
In cells from wild-type mice cultured in Th17-polarizing condi-
tions, the inducible cAMP early repressor (ICER) isoform of the
cAMP response element modulator transcription factor binds
to the Il17a promoter and drives Th17 cell generation. ICER rein-
forces this differentiation by also binding to the Gls1 promoter,
increasing Gls1 levels and consequent glutamine utilization
(Kono et al., 2018). Gls1 deficiency impairs Th17 cell differentia-
tion by limiting aKG supply. aKG is a cofactor for DNA and his-
tone demethylases, which modify chromatin methylation to
impact gene expression (Xiao et al., 2012). Gls1 disruptionCell Metabolism 32, August 4, 2020 3
Figure 1. Amino Acids Support Glycolysis
and Mitochondrial Metabolism
Amino acids influence cellular metabolism by
contributing to glycolysis, and the tricarboxylic
acid (TCA) cycle and OXPHOS in themitochondria.
Leucine and isoleucine increase translocation of
the glucose transporters GLUT1 and GLUT4 to the
cell surface in muscle cells and provide CoA in-
termediates to the TCA cycle, as does valine.
Serine activates the key glycolytic enzyme PKM2
in macrophages and can increase translation of
mitochondrial proteins in T cells, including those of
the electron transport chain. PKM2 activity is also
needed for T cell differentiation and cytokine pro-
duction. While pyruvate can be used to make
alanine, activated T cells decrease alanine syn-
thesis from pyruvate, in order to preserve pyruvate
metabolism to acetyl-CoA for TCA cycle activity. In
macrophages and plasma cells, glutamine sup-
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ferentiation, by altering the effects of aKG on chromatin (John-
son et al., 2018). At the same time, Gls1 deficiency increases
the transcription factor T-bet to promote differentiation and
effector function of Th1 and CD8
+ CTLs. Restricting glutaminol-
ysis may increase glutamine availability for other processes, or
may limit aKG to generate an epigenetic landscape supporting
T-bet-mediated Th1 cell differentiation and function. Therapeuti-
cally, Gls1 inhibition ameliorates hyperinflammation in experi-
mental autoimmune encephalomyelitis (EAE) (Kono et al., 2018)
and in a model of rheumatoid arthritis (Takahashi et al., 2017).
Downstream of glutamine uptake, glutamine degradation by glu-
taminolysis is a major catabolic pathway supporting the function
of specific T cell subsets.
Glutamine metabolism differs between different immune cell
types. IL-2/IL-12-induced Myc-dependent natural killer (NK)
cell activation requires Slc7a5-mediated glutamine uptake (Lof-
tus et al., 2018). Glutamine acquisition, not degradation, is
important in this context, as glutamine withdrawal, but not gluta-
minolysis blockade, inhibits NK cell activation. NK cells could
instead use glutamine for glutathione or hexosamine synthesis.
In contrast, glutaminolysis supports antibody production by acti-
vated B cells. Overexpression of the let-7adf microRNA cluster
represses ASCT2 and Gls1 expression in activated B cells,
decreasing IgM and IgG production (Jiang et al., 2018). Gls1 in-
hibition may be the important event here, as B cells lacking
ASCT2 develop and proliferate normally, and antibody produc-4 Cell Metabolism 32, August 4, 2020tion in ASCT2-deficient mice in response
to Bordetella pertussis is normal (Masle-
Farquhar et al., 2017).
Anaplerosis is a mechanism of replen-
ishing TCA cycle intermediates that have
been removed for biosynthetic reactions.
Glutamine anaplerosis to aKG is
increased in pro-inflammatory M1-like
macrophages, and, due to a break in the
TCA cycle, causes a build-up of succi-
nate, which drives IL-1b production. Nitric
oxide (NO)-mediated inhibition of pyru-vate dehydrogenase and aconitase-2 limits entry of metabolites
into the TCA cycle, promoting this glutamine anaplerosis to aKG
in inflammatorymacrophages (Palmieri et al., 2020). Glutamine is
needed to support LPS induction of IL-1 production by macro-
phages (Wallace and Keast, 1992), though it does not appear
to be required for M1-like macrophage development. Glutamine
flux into the TCA cycle underlies M2-like macrophage polariza-
tion by IL-4 (Jha et al., 2015; Liu et al., 2017). Plasma cells also
use glutamine for anaplerotic glutamate and aspartate replace-
ment (Lam et al., 2018). In contrast, activated NK cells use
some glutamine to replenish TCA cycle intermediates and in-
crease OXPHOS, but the glucose-supplied citrate-malate shut-
tle has a bigger role in driving TCA cycle activity in these cells
(Loftus et al., 2018). NKT cells, a cell type that shares features
of both innate and adaptive immune cells and express a highly
restricted TCR repertoire, need glutamine for survival and prolif-
eration, though how this glutamine is used is unknown (Kumar
et al., 2019). Clearly, many immune cells increase glutamine up-
take. Glutaminolysis supports the function of some of these im-
mune cells, while others funnel glutamine into other metabolic
pathways. Improved understanding of glutamine utilization in
different cell types will enable more specific targeting of gluta-
mine metabolism in a therapeutic setting.
Branched-Chain Amino Acids Provide TCA Cycle
Intermediates
Glutamine is not the only amino acid that supports metabolic re-
programming by supplying TCA cycle metabolites. The
Box 1. How Metabolism Links to Immune Cell Activation and Function
Immune cell activation inducesmetabolic reprogramming compared to unstimulated or naive immune cells. Pro-inflammatoryM1-
like macrophages dampen OXPHOS and rely on glycolysis, the pentose phosphate pathway, and fatty acid synthesis (Krawczyk
et al., 2010; Newsholme et al., 1986; Tannahill et al., 2013). M2-like macrophages, which promote anti-helminth responses and
resolve inflammation, rely more on the TCA cycle to support OXPHOS, as well as FAO (Huang et al., 2014; Vats et al., 2006).
DCs also upregulate glycolysis upon activation (Wculek et al., 2019). Upon TCR stimulation, naive T cells proliferate and differen-
tiate into different subtypes. Glycolysis and OXPHOS drive proliferation and cytokine production by Teff cells (Chang et al., 2013;
Sena and Chandel, 2012), while CD8+ Tmem cell generation and survival depend on OXPHOS and FAO (Pearce et al., 2009; van der
Windt et al., 2012). Naive and regulatory CD4+ T cells engage FAO (Beier et al., 2015), while glycolysis predominates in Th1, Th2,
and Th17 effector CD4
+ T cells (Gerriets et al., 2015). B cell receptor (BCR) stimulation of naive B cells increases glycolysis and
OXPHOS (Akkaya et al., 2018), while antibody-secreting cells rely on sustained glutamine consumption (Garcia-Manteiga et al.,
2011). These pathways are interlinked and co-regulated, and increased use of a particular pathway does not mean that other path-
ways are completely abandoned. Acquisition of energy and use of metabolites is fundamental to cell function, and immune cells
can quickly switch between metabolic pathways to support various activities. Nutrient supply and transporter expression dictate
metabolic pathway utilization, underlying how varying microenvironments and signals can alter immune cell function.
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valine provide the coenzyme A (CoA) derivatives acetyl-CoA
and succinyl-CoA, which enter the TCA cycle (Neinast et al.,
2019). Leucine transamination also produces glutamate, which
feeds the TCA cycle via aKG. Acetyl-CoA condenses with oxalo-
acetate to form the TCA intermediate citrate. Similar to glutamine
transporters, large neutral amino acid transporters are increased
upon immune cell activation. L-type amino acid transporter 1
(LAT1; Slc7a5) is an excellent example of how an amino acid
transporter can link pathogen infection to the immune response.
In vivo listeria infection increases Slc7a5 expression on T cells,
and IL-2 sustains this expression, maintaining continuous
BCAA supply to the activated T cells (Sinclair et al., 2013). TCR
stimulation of human T cells upregulates Slc7a5 (Hayashi et al.,
2013), as does IL-18 stimulation of NK cells (Almutairi et al.,
2019). Slc7a5 inhibition dampens IFN-g and IL-17 production
(Hayashi et al., 2013), and Th1 and Th17 cell development, but
Treg cells develop normally (Sinclair et al., 2013). Slc7a5-deficient
T cells cannot undergo the mTORC1- and Myc-dependent in-
crease in glycolysis necessary for activation (Sinclair et al.,
2013). Strikingly, knockout of Slc7a5 alone largely phenocopies
the effect of Myc deficiency on the activated CD4+ T cell prote-
ome, and impairs T cell growth (Marchingo et al., 2020). The fact
that loss of a single transporter has effects as drastic as knocking
out such a central regulator as Myc illustrates the importance of
amino acid transport and acquisition for T cell function.
Slc7a5 also underlies macrophage metabolic rewiring. LPS in-
creases BCAA transporter expression in macrophages, and
macrophages lacking leucine transport via Slc7a5 have reduced
glycolysis and IL-1b production (Yoon et al., 2018). CD98 is
needed for Foxp3+ Treg (Ikeda et al., 2017) formation, prolifera-
tion of T and B cells (Cantor et al., 2009, 2011), and NK cell cyto-
kine production (Jensen et al., 2017). CD98 expression is high in
antibody-secreting plasma cells, and its absence impairs anti-
body production. Cell surface expression of CD98 correlates
with plasma cell longevity (Shi et al., 2015; Tellier et al., 2016),
and plasma cells with high surface levels of CD98 secrete
more antibodies than short-lived plasma cells with low surface
CD98 expression. Interestingly, these populations with very
different longevities have similar transcriptional profiles, but
metabolic parameters such as CD98 expression, glucose up-take, and pyruvate-dependent mitochondrial respiration are bet-
ter able to distinguish between long- and short-lived plasma cells
(Lam et al., 2016, 2018). Understanding plasma cell longevity
and persistence is beneficial in terms of generating long-lived im-
mune responses after vaccination (White et al., 2015). Given
these clear differences in metabolic signatures, manipulation of
plasma cell metabolism is an intriguing potential method to in-
crease the duration of humoral immunity to pathogens.
Branched-chain amino acid aminotransferase (BCAT1), the
first enzyme of BCAA catabolism, transaminates BCAAs to
branched-chain a-keto acids, which are decarboxylated to
form CoA derivatives (Brosnan and Brosnan, 2006). BCAT1 inhi-
bition restrains both glycolysis and oxygen consumption, and
limits production of itaconate (Papathanassiu et al., 2017), an
anti-inflammatory metabolite (Mills et al., 2018). Older work
showed that mice fed diets lacking BCAAs generate defective
antibody and cytotoxic T cell responses in response to Salmo-
nella typhimurium (Petro and Bhattacharjee, 1981) or mammary
adenocarcinoma (Jose and Good, 1973), while BCAA supple-
mentation enhanced liver CD8+ T cell activity in a murine model
of liver cirrhosis (Tsukishiro et al., 2000), and increased lympho-
cyte numbers and responses to skin antigens in patients with
post-operative trauma or sepsis (Cerra et al., 1984). Valine
boosts DC IL-12 production in cirrhotic patients (Kakazu et al.,
2007). BCAAs could also support metabolic reprogramming of
immune cells by stimulating glucose uptake to promote glycol-
ysis. In rat muscle cells, leucine and isoleucine increase translo-
cation of the glucose transporters (GLUTs) GLUT1 and GLUT4 to
the cell surface to increase glucose uptake (Nishitani et al.,
2005), in a process that may depend on PI3K and protein kinase
C (Doi et al., 2005a). Leucine-supplied acetyl-CoA could also
acetylate and activate mTORC1 (Son et al., 2019), further rein-
forcing enhanced glycolysis.
Serine Promotes Glycolysis and Mitochondrial
Metabolism
Serine also increases glycolytic flux. It ligates and allosterically
activates pyruvate kinase M2 (PKM2) (Chaneton et al., 2012),
which converts phosphoenolpyruvate to pyruvate in the last
step of glycolysis. LPS induces PKM2 in macrophages to drive
the metabolic switch toward glycolysis and IL-1b induction
(Palsson-McDermott et al., 2015). TCR stimulation of CD4+Cell Metabolism 32, August 4, 2020 5
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10.1016/j.cmet.2020.06.010T cells increases nuclear translocation of PKM2 (Wang et al.,
2011), which increases glycolysis to support Th1 and Th17 cell
generation, and tumor necrosis factor (TNF) and IL-17 produc-
tion. Inhibition of PKM2 nuclear translocation by inducing its tet-
ramerization limits Th1 and Th17 generation and cytokine pro-
duction, and inhibits the development of EAE, a murine model
of neural inflammation including multiple sclerosis (Angiari
et al., 2020). Serine limitation also inhibits PKM2 to decrease
excessive macrophage activation in atherosclerosis (Shirai
et al., 2016), and inhibition of serine synthesis decreases IL-1b
and TNF production in LPS-induced endotoxemia (Rodriguez
et al., 2019).
Serine also supports mitochondrial metabolism. The catabolic
enzyme serine hydroxymethyltransferase (Shmt2) is needed for
mitochondrial translation and respiratory activity (Minton et al.,
2018), and Shmt2-deficient mice have respiratory defects (Tani
et al., 2018). This effect depends on generation of one-carbon
(1-C) units from serine (Stover and Schirch, 1990). 1-C units
are used for processes including nucleotide synthesis and
methionine recycling, and enzymes of mitochondrial 1-C meta-
bolism are upregulated in proliferative tissues (Mejia and MacK-
enzie, 1985; Nilsson et al., 2014). Mitochondrial translation
initiation depends on the modified tRNA, N-formylmethionine-
tRNAMet (fMet-tRNAMet), formed from serine via Shmt2. 1-C
unit supplementation rescues defects in respiration and mito-
chondrial translation in Shmt2-deficient Jurkat cells. This
pathway seems to be especially important in low-glucose condi-
tions that induce cells to increase mitochondrial metabolism in a
compensatory manner, so it may also be important for immune
cells that switch from glycolytic to mitochondrial metabolism.
However, even T cells with sufficient glucose to support
increased glycolysis, OXPHOS, and effector function rely on 1-
C metabolism downstream of serine (Ma et al., 2017). Methylene
tetrahydrofolate dehydrogenase 2 catalyzes intermediate steps
in mitochondrial fMet-tRNAMet formation, generating NADH. In
pancreatic tissue with impaired mitochondrial respiration, this
NADH can accumulate to toxic levels, inhibiting cell growth
(Yang et al., 2020). It would be intriguing to investigate whether
cells that switch away from mitochondrial metabolism concom-
itantly decrease this serine catabolism to avoid such toxicity and
permit continued growth.
While other amino acids can fuel glycolysis and the TCA cycle,
sometimes T cells do not use them for these pathways. Extracel-
lular alanine is necessary for early activation of T cells (Ron-Harel
et al., 2019). While alanine can be metabolized to pyruvate, the
end product of glycolysis, it is not used for this purpose in acti-
vated T cells, and is instead used for protein synthesis. Further,
although alanine can be synthesized from glucose via alanine
aminotransferase, expression of this enzyme is low in T cells
early after activation, which instead take up extracellular alanine
via SNAT1 (Matheson et al., 2015). This preserves pyruvate for
acetyl-CoA production, TCA cycle activity, and OXPHOS, while
the extracellular alanine is used for protein synthesis.
Amino Acids Control Sulfur and Redox Metabolism
Immune cell activation frequently depends on increased ROS
production (Kaminski et al., 2012; Sena et al., 2013), which can
be generated by the mitochondria and cytoplasmic NADPH ox-
idases. LPS induces ROS production in macrophages to drive6 Cell Metabolism 32, August 4, 2020cytokine production (Bulua et al., 2011) and bacterial killing
(West et al., 2011). ROS can activate the nuclear factor of acti-
vated T cells (NFAT), a T cell-specific transcription factor that
induces IL-2 production and cell-cycle engagement, increasing
T cell proliferation (Sena et al., 2013). Elevated ROS drive cal-
cium signaling, promoting nuclear translocation of NFAT to in-
crease transcription of target genes, including Myc, needed for
T cell activation andmetabolic reprogramming toward increased
glycolysis and glutaminolysis. The balance of ROS is critical, as
an excess of these free radicals can cause cell damage and sub-
sequent pathology (Chouchani et al., 2014; Sena and Chandel,
2012). BCR stimulation of naive B cells also induces massive
ROS production and calcium-induced mitochondrial dysfunc-
tion. This causes activation-induced cell death unless the B
cell also receives costimulatory signals such as TLR or CD40
engagement, which prevent the mitochondrial dysfunction
through an uncharacterized mechanism (Akkaya et al., 2018).
Thus, cells have multiple antioxidant mechanisms to control
ROS levels, and amino acids are crucial formaintaining these de-
fenses and redox balance (Figure 2). Major cellular antioxidants
include glutathione, thioredoxins, glutaredoxins, superoxide dis-
mutase, and catalase (Sies et al., 2017; Zhang and Hannink,
2003). For example, glutathione peroxidase 4 prevents lipid
oxidation to support T cell survival and activation (Matsushita
et al., 2015). Immune cells have harnessed these antioxidant
systems to modulate activation and cytokine production.
Glutathione Is Needed for T Cell and Macrophage
Function
Glutathione is a small molecule composed of glycine, glutamate,
and cysteine. Thus, supply of these amino acids dictates gluta-
thione levels. The reduced form of glutathione (GSH) is oxidized
to form a disulfide bridge with another GSHmolecule, becoming
oxidized glutathione (GSSG). GSSG is recycled to GSH by gluta-
thione reductase (GSR), maintaining an intracellular GSH pool
that detoxifies ROS (Lu, 2009). Increased ROS production
upon immune cell activation increases demand for GSH, and
such increased GSH synthesis requires a supply of its compo-
nent amino acids. GSH levels are indeed increased upon T cell
activation (Mak et al., 2017), and de novo GSH synthesis, rather
than recycling from GSSG, is important for T cell differentiation
and function (Lian et al., 2018). Deficiency of the GSH synthetic
enzyme glutamate cysteine ligase (GCLC), but not that of the
GSH recycling enzyme GSR, reduces activated T cell viability,
proliferation, and expression of the activation marker CD25
due to aberrant ROS balance (Lian et al., 2018). Glutamine sup-
plies glutamate for such de novo GSH synthesis, and Gls1 inhi-
bition antagonizes T cell differentiation and function. Glutathione
also impacts the increased glycolysis and glutamine utilization
underlying T cell activation. Conditional Gclc deletion abolishes
mTORC1 activation, the nuclear accumulation of NFAT, and
the Myc-dependent switch toward glycolysis and glutaminolysis
in activated CD4+ and CD8+ T cells (Mak et al., 2017). These cells
initially activate normally but cannot meet the metabolic de-
mands for expansion and fail to proliferate (Mak et al., 2017). In
contrast, Gclc-deficient Treg cells increase mTOR activity, which
inhibits Foxp3 expression and Treg suppressive function (Kurnia-
wan et al., 2020). Gclc-deficient Treg cells increase serine import
and synthesis, possibly in an attempt to generate glycine for
GSH, via Shmt enzymes. In this context of impaired GSH
Figure 2. Sulfurous Amino Acids Maintain
Redox Balance and Drive Protein Synthesis
Cysteine, glutamine, and glycine make the anti-
oxidant glutathione (GSH), which is oxidized to
GSSG to detoxify reactive oxygen and maintain
intracellular redox balance. T cells increase GSH
synthesis upon activation, and B cells and mac-
rophages also need GSH to regulate redox status
after ROS production upon activation. DCs can aid
this process by providing cysteine to other immune
cells. Methionine and serine can be metabolized to
cysteine, with methionine also generating S-ad-
enosylmethionine (SAM), which provides methyl
groups to modify immune effector proteins and
nucleic acids, facilitating cytokine gene expression
in T cells and macrophages, and both innate and
adaptive immune memory. Cysteine is a sulfur
donor for processes including tRNA thiolation,
which aids translation, and iron sulfur (FeS) cluster
synthesis. FeS clusters are key for the activity of a
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10.1016/j.cmet.2020.06.010synthesis, serine instead activates mTOR, which inhibits Foxp3
expression. Serine limitation restores Foxp3 expression and
Treg suppressive activity, decreasing lethal auto-inflammation
in vivo. So one function of GSH in Treg cells is to restrict serine
metabolism, thereby maintaining their suppressive function.
Macrophages also use serine to generate glycine for GSH,
needed for LPS-induced IL-1b mRNA expression (Rodriguez
et al., 2019). This serine-glycine-GSH regulatory loop illustrates
how amino acids and small peptides regulate the metabolism
of other amino acids.
Cysteine/cystine import supports immune cell function, at
least in part by facilitating GSH synthesis. Resting B cells do
not express xCT (Slc7a11) but, upon activation, increase xCT
expression and cystine import, possibly to produce GSH to
counter the ROS production that would otherwise cause activa-
tion-induced cell death (Vene´ et al., 2010). LPS activation of DCs
increases system xc
 cystine-glutamate antiporter activity
(D’Angelo et al., 2010), which may be needed to increase GSH
synthesis to counter the increased ROS production upon activa-
tion. DCs can also export GSH to shape the extracellular redox
environment, particularly around the immune synapse between
DCs and T cells. This GSH is broken down to cysteine, which de-
creases extracellular redox potential and promotes CD4+ Teff cell
proliferation, possibly as CD4+ T eff cells acquire this cysteine for
GSH production and consequent proliferation (Yan et al., 2009).
It alters the redox status of proteins on the T cell surface, with as
yet unknown consequences. Further, co-culture of Treg cells withDCs and CD4+ Teff cells depletes extra-
cellular cysteine, possibly explaining
some of the suppressive effect of Treg
cells on Teff cell proliferation. Thus, innate
immune cells modulate amino acids in or-




Cysteine is a key amino acid for GSH
function, as it supplies the sulfur neces-
sary for formation of the disulfide bridgein GSSG, but its roles extend beyond GSH synthesis. Cysteine
predominantly exists in its oxidized form, cystine, in the oxidative
extracellular environment. Cystine uptake is needed for T cell
activation (Srivastava et al., 2010), proliferation (Levring et al.,
2012), and DNA synthesis (Levring et al., 2015). Blockade of
cystine uptake by T cells is protective against EAE (Evonuk
et al., 2015). Similar to B cells, resting T cells do not express
xCT, but activated CD4+ and CD8+ human T cells increase
xCT to promote cystine uptake (Siska et al., 2016). Blockade of
this antiporter in monocytes inhibits their differentiation into
DCs in response to IL-4 and granulocyte-macrophage colony-
stimulating factor, and its inhibition in mature DCs impairs anti-
gen presentation to CD4+ T cells, as well as cross-presentation
to CD8+ T cells (D’Angelo et al., 2010).
Only two of the proteinogenic amino acids contain sulfur, and
they are intimately related. Methionine transulfuration to cysteine
maintains cysteine-dependent processes when extracellular
cysteine is in limited supply. Via S-adenosylmethionine (SAM)
and S-adenosylhomocysteine (SAH), methionine can be used
to produce homocysteine, which forms cystathionine when
combined with serine by cystathionine-b-synthase (Stipanuk,
1986). This in turn can be metabolized by cystathionine-g-lyase
to form cysteine. Cysteine limitation induces expression of these
transulfuration enzymes (Zhu et al., 2019). This process is known
to occur in the liver and has now been demonstrated in cancer
cells (Zhu et al., 2019), though it has not yet been investigated
in an immune cell context.Cell Metabolism 32, August 4, 2020 7
Figure 3. Amino Acids Influence Cell
Function by Supplying Intermediates for
Protein and Nucleotide Modifications
Amino acids provide a variety of functional groups
that can be conjugated to intracellular targets.
Methionine, arginine, glutamine, and the
branched-chain amino acids provide in-
termediates for post-translational modifications
(PTMs) of proteins. Such PTMs can alter the ac-
tivity of metabolic pathways and immune cell
function by changing the activity of target proteins.
Many amino acids have not yet been investigated
in this context but are likely to provide in-
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10.1016/j.cmet.2020.06.010Sulfur supply from cysteine is also critical for maintaining mito-
chondrial metabolism via the synthesis of iron-sulfur (FeS) clus-
ters (Lill, 2009), key components of many enzymes, including
some electron transport chain (ETC) subunits. The cysteine de-
sulfurase NFS1 removes sulfur from cysteine for FeS clusters,
and cysteine limitation decreases FeS cluster synthesis. Loss
of FeS clusters can itself impact metabolic pathways, as the
FeS cluster-containing enzyme aconitase can no longer metab-
olize citrate, leading to a buildup of this TCA cycle intermediate
and its use in fatty acid synthesis (Crooks et al., 2018). Argi-
nine-derived NO destabilizes FeS clusters (Drapier, 1997),
demonstrating a mechanism by which NOmay antagonize mito-
chondrial metabolism in M1-like macrophages. Besides
decreasing mitochondrial metabolism, decreasing FeS cluster
synthesis leads to an excess of free iron, as it is not being
used for these clusters. This can drive ferroptosis, an iron-
dependent form of cell death (Dixon et al., 2012). Cystine-GSH
crosstalk regulates amino acid signaling and ferroptosis (Yu
and Long, 2016). Indeed, maintaining expression of NFS1 can
protect against ferroptosis, as occurs in tumor cells (Alvarez
et al., 2017).
NFS1 also uses the sulfur atom of cysteine to thiolate tRNA, as
shown in Saccharomyces cerevisiae (Nakai et al., 2004). Lysine,
glutamine, and glutamate tRNAs can be thiolated on the uridine
nucleotide in the wobble position (U34), easing translation by
aiding tRNA translocation through the ribosome (Phelps et al.,
2004; Yarian et al., 2002). Genes enriched in lysine, glutamine,
and glutamate codons occur frequently in proteins important8 Cell Metabolism 32, August 4, 2020for translation and growth. During sulfur
limitation, i.e., methionine and cysteine
limitation, such tRNA thiolation is
decreased, slowing translation when nu-
trients are limiting (Laxman et al., 2013).
FeS cluster synthesis and tRNA thiolation
have not yet been investigated in immune
cells, but may have a role to play here, as
maintenance of mitochondrial meta-
bolism and increased translation underlie
immune cell activation. It is easy to ima-
gine a situation in which sulfur could
become limiting in T cells and macro-
phages, which increase ROS upon
activation, and consequently induce pro-
duction of antioxidants, including GSH(Mak et al., 2017). Prioritizing such GSH production could limit
the use of sulfur for translation, and eventually curb immune
cell proliferation and effector function. Such sulfur competition
could be exacerbated in sulfur-deficient microenvironments,
and could contribute to differences in proliferation in different en-
vironments; for example, the continued T cell expansion in lymph
nodes versus decreased proliferation in tissue populations.
Amino Acids Support Nucleic Acid and Protein
Modification
Amino Acids Supply Methyl Groups for Methylation
Besides its contribution to sulfur metabolism, methionine do-
nates methyl groups for methylation of proteins and nucleotides
to modulate their function (Figures 2 and 3). Histone and DNA
methylation can promote or inhibit transcription by altering the
accessibility of DNA to transcriptional machinery (Allis and Jenu-
wein, 2016). Both inhibitory (histone H3 lysine 27, H3K27) and
activating (H3K4) histone methylation occur upon T cell activa-
tion, underlying transcriptional remodeling (Henning et al.,
2018; Sinclair et al., 2019). RNA methylation controls such pro-
cesses as mRNA binding to translation initiation factors, mRNA
stability, and splicing (Aregger and Cowling, 2017; Varshney
et al., 2018). Adenosine methylation to control mRNA stability
is important for T cell homeostasis, and T cells lacking the N6-
methyladenosine methylation (m6A) of RNA do not expand and
differentiate (Li et al., 2017). Methionine supplies methyl groups
by producing SAM, the methyl donor for DNA, RNA, and protein
methyltransferases (Lu, 2000), which transfer the methyl group
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10.1016/j.cmet.2020.06.010from SAM to a substrate, generating SAH and amethylated sub-
strate (Figure 2). S-adenosylhomocysteine hydrolase then me-
tabolizes SAH to homocysteine (Hcy). Hcy can be used to
generate cysteine, a process that is increased in activated
CD4+ T cells (further illustrating the demand for cysteine in acti-
vated T cells) or can be recycled to methionine. Th17 cells
starved of methionine or subjected to methionine cycle inhibition
exhibit reduced H3K4 methylation at the Il17a promoter and
decrease IL-17 production, while methionine-starved Th1 cells
produce less IFN-g (Roy et al., 2020). Further, dietary methionine
restriction decreases the numbers of IL-17- and IFN-g-produc-
ing cells in mice with EAE, delaying the onset of disease and
reducing its severity.
As well as its acute impact on immune cell function, methio-
nine status can have longer-lasting effects by epigenetically
modifying immune cell memory. Trained immunity is a program
of long-term change that occurs in innate immune cells due to
pathogen exposure, facilitating increased responses upon re-
stimulation (Netea et al., 2016). b-glucan training of human pe-
ripheral blood mononuclear cells enhances H3K4 trimethylation
at the promoters of genes for cytokines and immune signaling
factors, including MyD88, TNF, and IL-6 (Quintin et al., 2012).
This may underlie the boost in cytokine production by these cells
upon re-exposure to Candida albicans. Adaptive immune mem-
ory also relies on histone methylation. Activating histone marks
for cytokines (IL-17, IFN-g) and T cell-specific transcription fac-
tors (T-bet, ROR-g) are enriched in memory CD4+ T cells
compared to naive CD4+ T cells, and this poised chromatin state
leads to more rapid induction of these cytokines in memory
T cells upon stimulation (Barski et al., 2017; Durek et al., 2016).
Similarly, the genome-wide pattern of both stimulatory (H3K4)
and inhibitory (H3K27) methylation in memory CD8+ T cells is
more similar to Teff cells than to naive T cells (Crompton et al.,
2016; Russ et al., 2014). Genes for proteins underlying CD8+
memory T cell formation, such as the transcription factor B-
lymphocyte-inducedmaturation protein (BLIMP)1, and cytotoxic
effector molecules granzme A and perforin, are hypermethylated
on histone H3 (Araki et al., 2009b), facilitating increased expres-
sion of these genes and illustrating how epigenetic marks sup-
port memory T cell function. Histonemethyltransferasesmediate
histone methylation, using SAM as a methyl donor and produc-
ing SAH. SAH can act as a competitive inhibitor of SAM, and thus
the balance between SAM and SAH, and flux through the methi-
onine cycle, could impact the extent of histone methylation.
Methionine Transport Underlies T Cell Activation
Antigen-stimulated T cells increase and sustain methionine
transport into the cell, which is a rate-limiting step for the supply
of methyl donors and methylation of targets in activated T cells
(Sinclair et al., 2019). Expression of methionine transporters is
restricted to activated T cells, so even though naive T cells
have enzymes of methionine metabolism, they cannot transport
sufficient methionine into the cell to increase protein synthesis.
Thus, control of cellular methionine levels modulates T cell sta-
tus. Only T cells that can increase methionine transport will
have sufficient methionine to drive methylation, protein synthe-
sis, and proliferation. Slc7a5 is the main methionine transporter
in activated T cells and is important for T cell differentiation (Sin-
clair et al., 2013, 2019). Methionine supply is sensed by SAM-
TOR,which detects SAMand consequently modulatesmTORC1signaling (Gu et al., 2017). This illustrates how an amino acid
metabolite, rather than the amino acid itself, is sensed by
mTORC1 as a readout of amino acid levels. TCR stimulation pro-
motes flux through the methionine cycle, demonstrated by
increased production of SAH and Hcy, and CD4+ T cells acti-
vated in the absence of methionine have proliferation defects,
but normal expression of activation markers, and lower fre-
quency of IFN-g-producing cells (Sinclair et al., 2019). Methio-
nine restriction limits T cell activation by blunting Myc induction,
which is critical for T cell activation (Wang et al., 2011).
Arginine Contributes to Polyamine Metabolism
Methylation is not the only PTM controlled by amino acid supply
(Figure 3). Arginine metabolism also leads to structural modifica-
tion of proteins to influence immune cell function (Geiger et al.,
2016; Puleston et al., 2019). Arginase I metabolizes arginine to
ornithine, which feeds polyamine synthesis, including spermi-
dine production. Highlighting the inherent interconnectedness
of metabolic pathways, spermidine production also requires
SAM. Thus, its synthesis may report that there is adequate
nutrient supply to multiple metabolic pathways, and may signal
that various metabolites and building blocks are present in suffi-
cient levels to coordinately fuel biosynthesis, and allow prolifer-
ation to progress. Spermidine is used tomake the unusual amino
acid hypusine, which post-translationally modifies only one
known target, eukaryotic translation initiation factor 5a (eIF5a)
(Park et al., 1981), which drives translation elongation and termi-
nation (Saini et al., 2009; Schuller et al., 2017). This hypusination
is critical for eIF5a to maintain expression of ETC enzymes and
OXPHOS activity (Puleston et al., 2019), a process that is upre-
gulated in IL-4-stimulated M2 macrophages. Arginase I activity
is in fact a marker of alternative activation, as its activity is highly
induced in M2-like macrophages, but reduced in M1-like macro-
phages, and arginine usage differs markedly in M2- versus M1-
like macrophages (Rath et al., 2014). Mouse M1-like macro-
phages metabolize arginine via inducible NO synthase (iNOS)
to produce citrulline and NO, which inhibits OXPHOS. As a
consequence, glycolysis increases and supports pro-inflamma-
tory macrophage function, including cytokine production. In M2-
like macrophages, arginase I metabolizes arginine to ornithine
and urea. This use of arginine by macrophages may also limit
arginine to inhibit T cell activation (Pesce et al., 2009; Rodriguez
et al., 2004). While arginase I activity is reduced in M1-like
macrophages, it is not absent, and ornithine metabolism to poly-
amines by ornithine decarboxylase (ODC) limits M1-like macro-
phage activation and inflammation during bacterial infection.
ODC deletion increases inflammatory gene expression due to
altered histone methylation and acetylation, and re-addition of
putrescine reverses these chromatin modifications and avoids
the hyperinflammation caused by ODC deficiency (Hardbower
et al., 2017). Polyamine production supports the function of
M2-like macrophages while limiting inflammatory activity of
M1-like macrophages.
Macrophages take up arginine from apoptotic cells, which is
metabolized via arginase I and, in a putrescine-dependent
manner, activates the actin regulatory protein Rac1 to enable
further apoptotic cell internalization, ensuring a supply of metab-
olites for the macrophage (Yurdagul et al., 2020). Myeloid-
derived suppressor cells (MDSCs) also increase arginine
metabolism via arginase to limit arginine supply to T cellsCell Metabolism 32, August 4, 2020 9
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10.1016/j.cmet.2020.06.010(Fletcher et al., 2015), and inhibit NK cell function and IFN-g pro-
duction in a similar manner (Goh et al., 2016; Lamas et al., 2012).
Arginine-starved NK cells have reduced viability, expression of
NK cell activating receptors NKp46 and NKp30, and diminished
IFN-g (Lamas et al., 2012). This phenomenon is exploited in
chronic hepatitis C infection by the virus to limit antiviral immune
responses. Similarly, Th1 polarization promotes arginase I activ-
ity. Arginine drives a metabolic switch toward oxygen consump-
tion and increases spare respiratory capacity in activated T cells,
and supports CD4+ and CD8+ T cell survival (Geiger et al., 2016).
Polyamine replacement partially rescues the detrimental effects
of glutamine deprivation on T cell activation, indicating that one
use of glutaminemay be its metabolism to arginine for polyamine
synthesis (Wang et al., 2011). Spermidine also has anti-aging
effects (Madeo et al., 2018), which may result from its enhance-
ment of immune cell function. Spermidine ameliorates the aging-
induced decline in CD8+ T cell responses to infection and
vaccination in an autophagy-dependent manner (Puleston
et al., 2014), and enhances anti-cancer immune responses (Pie-
trocola et al., 2016). As spermidine levels decrease with age
(Pucciarelli et al., 2012), dietary supplementation of spermidine
(Kiechl et al., 2018) or enhancing spermidine production by intes-
tinal microbes (Kibe et al., 2014) may prove beneficial in extend-
ing lifespan, possibly by maintaining immune cell activity.
Glutamine Fuels the Hexosamine Biosynthesis Pathway
The hexosamine biosynthesis pathway (HBP) metabolizes gluta-
mine to uridine diphosphate N-acetyl-glucosamine (UDP-
GlcNAc). Glycosyltransferases use UDP-GlcNAc to glycosylate
targets including proteins and lipids, to form glycoproteins,
proteoglycans, and glycolipids (Lairson et al., 2008). Glutamine
starvation or increased glutaminolysis limits glutamine supply to
the HBP, thus reducing intracellular UDP-GlcNAc levels, with con-
sequences for T cell function (Grigorian et al., 2007; Lau et al.,
2007). N-linked glycosylation modulates TCR signaling and inter-
action with co-stimulatory molecules such as CD4 and CD8 (De-
motte et al., 2008; Grigorian et al., 2009). Increased N-glycan
branching of the TCR reduces its activity, inhibiting T cell prolifer-
ation (Demetriou et al., 2001), while N-glycan branching of the
inhibitory molecule cytotoxic T-lymphocyte-associated protein
(CTLA)4 promotes its retention on the cell surface, compounding
this anti-growth effect (Chen et al., 2009). Flux through the HBP
and N-linked glycosylation also regulate Th17 cell differentiation.
High glycolysis and glutaminolysis in Th17 cells restrict HBP activ-
ity, limiting N-glycan branching and promoting Th17 cell genera-
tion (Araujo et al., 2017). Convincingly, addition of glutamine or
GlcNAC, or glutaminolysis inhibition, reverses these effects and
blocks Th17 cell production while driving Treg cell differentiation.
Antibody-secreting plasma cells also glycosylate antibodies to
expand the antibody repertoire, as differential glycosylation of an-
tibodies changes protein folding and interactions of antibodies
with Fc receptors (Jennewein and Alter, 2017). It remains un-
known whether different plasma cell subsets, or plasma cells in
different nutrient environments, vary in terms of glutamine uptake
and HBP usage, thereby generating different antibodies in a
context-dependent manner.
UDP-GlcNAc is also the donor substrate for O-GlcNAc trans-
ferase (OGT), which catalyzes O-GlcNAcylation, a PTM in which
O-GlcNAc is added to target proteins (Hart et al., 2007). TCR stim-
ulation and c-Myc activation promote O-GlcNAcylation in CD4+10 Cell Metabolism 32, August 4, 2020T cells, which requires an increased supply of UDP-GlcNAc and
therefore increased glutamine uptake. NFAT and c-Myc them-
selves are activated and stabilized by this modification (Golks
et al., 2007; Swamy et al., 2016). OGT is needed for thymic
T cell self-renewal, and T cell activation and expansion (Swamy
et al., 2016), as well as nascent RNA synthesis, IL-2 production,
and proliferation in primary human T cells (Lund et al., 2016). O-
GlcNAcylation of PKM2 promotes its nuclear translocation and
activation of glycolysis in leukemic cells and solid tumors (Wang
et al., 2017b). Glutamine, as well as glycine and cysteine, can
also be used for the S-glutathionylation modification, adding a
glutathione tripeptide to target proteins (Dalle-Donne et al.,
2009). It is unknown whether and how this modification functions
in immune cells. Overall, it is clear that TCR stimulation increases
UDP-GlcNAc production, which itself requires an increased sup-
ply of glutamine, again highlighting transport of glutamine into
the cell as a point of control of T cell function.
BCAAs Support Acetylation
BCAA metabolism provides acetyl-CoA derivatives that can be
used for acetylation. Leucine-derived acetyl-CoA is used to
acetylate the mTORC1 regulator Raptor via the EP300 acetyl-
transferase in HeLa cells (Son et al., 2019). This activates
mTOR, but it remains to be seen how specifically thismechanism
reports on leucine status, as numerous other inputs can generate
acetyl-CoA. Histone acetylation epigenetically modulates
immune cell activation. In general, histone acetylation makes
chromatin more accessible to transcriptional machinery and is
associated with increased transcription, while histone deacety-
lation is associated with repression of transcription (Kouzarides,
2007). Broad alterations in H3K27 acetylation accompany
macrophage differentiation, and differences in histone acetyla-
tion contribute to the induction of innate immune tolerance
(decreased responsiveness to restimulation) or training
(increased responsiveness to restimulation) (Saeed et al.,
2014). Genes involved in glycolysis and mTOR signaling exhibit
altered acetylation patterns upon b-glucan training of human pri-
marymonocytes (Cheng et al., 2014). Modulation of HDAC activ-
ity and promoter acetylation can both positively and negatively
regulate inflammatory gene expression. For example, broad-
spectrum HDAC inhibition limits LPS induction of TNF and IL-6
in macrophages, but increases IFN-b production (Roger et al.,
2011). More specific HDAC inhibition reveals that different
HDACs can have opposing effects. HDAC1 and HDAC8 inhibit
IFN-b expression, while HDAC6 promotes enhancer activity for
this cytokine (Nusinzon and Horvath, 2006). H3K9 deacetylation
mediated by HDAC3 limits M2-like macrophage activation by re-
pressing IL-4 induction of genes characteristic of M2-like macro-
phages (Mullican et al., 2011).
Non-histone protein acetylation also impacts immune cell
function. Activity of the central pro-inflammatory transcription
factor nuclear factor (NF) kB requires its acetylation (Yeung
et al., 2004), and NOD-, LRR-, and pyrin domain-containing pro-
tein (NLRP)3 acetylation promotes inflammasome activation (He
et al., 2020). Acetylation likely underlies the metabolic switches
accompanying immune cell activation, as the majority of glyco-
lytic and TCA cycle enzymes can be acetylated, with conse-
quences for enzymatic function. For example, glyceraldehyde
3-phosphate dehydrogenase acetylation increases its enzy-
matic activity in memory CD8+ T cells, boosting glycolysis to
Figure 4. Do Immune Cells and Tumor Cells
Compete for Amino Acids in the Tumor
Microenvironment?
Within the tumor microenvironment, cancer cells
and immune cells may compete for limited amino
acid resources. Restricting amino acid supply to
some immune cells, such as CD8+ Teff cells, de-
creases their proliferation and effector function,
thereby decreasing anti-tumor immunity. At the
same time, limitation of amino acid supply to
suppressive immune cells, such as Treg cells or
MDSCs, could antagonize their suppression of
effector cell function, thereby boosting anti-tumor
immunity. Increased consumption of amino acids
by tumor cells fuels their proliferation, growth, and
metastasis. Understanding and targeting amino
acid consumption and metabolism by tumor cells
and tumor-associated immune cells is likely to be
beneficial in cancer treatment.
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10.1016/j.cmet.2020.06.010support rapid recall responses and cytokine production (Balmer
et al., 2016). These memory CD8+ T cells increase acetate up-
take to expand their acetyl-CoA pool to support this increased
acetylation, but increased BCAA supply could have the same ef-
fect. Conversely, deacetylation mediated by HDACs can be anti-
inflammatory, and so limiting supply of BCAAs for acetylation
could achieve similar results.
Amino Acids Are Used for Immune Cell Nucleotide
Synthesis
Nucleotides are needed to make DNA and RNA during cell divi-
sion and transcription (Sigoillot et al., 2003). Both purine and py-
rimidine nucleotides promote activated T cell progression
through the cell cycle (Que´me´neur et al., 2003), and Myc in-
creases expression of nucleotide synthetic genes (Liu et al.,
2008). Aspartate and glutamine provide carbon skeletons for py-
rimidine ring formation, while glycine and tetrahydrofolate (THF)
from serine-glycine metabolism provide carbon for purine syn-
thesis (Lane and Fan, 2015). Nucleotides can partially rescue
the detrimental effects of glutamine deprivation on T cell activa-
tion, indicating that one function of glutamine in immune cell acti-
vation is provision of nucleotides (Wang et al., 2011).
CD8+ Teff cells increase expression of components of the
serine, glycine, one-carbon (SGOC) network upon activation,
and serine limitation impairs T cell proliferation, but not expres-
sion of the activation markers CD69, CD25, and CD44, or
production of IFN-g (Ma et al., 2017). These T cells need extra-
cellular serine to support purine nucleotide production, and
provision of serine-deprived T cells with formate and glycine is
sufficient to resume purine biosynthesis and T cell proliferation
during serine starvation (Ma et al., 2017). Serine is a major
carbon donor to the 1-C pathway. As already mentioned, the
mitochondrial form of the Shmt enzyme (Shmt2) is critical for
mitochondrial translation. The cytoplasmic form of this enzyme,
Shmt1, supports de novo nucleotide biosynthesis. Glycine has
also been reported to have anti-proliferative effects on T cells,
by opening a glycine-gated channel in the plasma membrane
to reduce intracellular calcium levels, which are necessary for
T cell activation and proliferation (Stachlewitz et al., 2000). These
differential effects of glycine may be due to the dose of glycine
used, or the timing of glycine supplementation.Aspartate is also needed for nucleotide synthesis. Jurkat cells
with inhibited ETC activity have decreased aspartate synthesis,
which slows proliferation in these cells (Birsoy et al., 2015). The
cytosolic aspartate aminotransferase GOT1 transaminates
aspartate to glutamate to transfer reducing equivalents to the
mitochondrial matrix (Toney, 2014) but, upon ETC inhibition,
acts in reverse to generate aspartate, to partially compensate
for the loss in mitochondrial aspartate synthesis. This reversal
supports proliferation of Jurkat cells with ETC inhibition (Sullivan
et al., 2015). It is intriguing to speculate that this process may
occur in cells that intentionally shut down mitochondrial meta-
bolism, for example via intracellular NO production in murine
M1-like macrophages. Mitochondrial metabolism also supports
aspartate synthesis by providing electron acceptors, such as O2.
Aspartate synthesis from glutamine requires electron acceptors
generated by mitochondrial metabolism. In the absence of such
electron acceptors, aspartate synthesis and nucleotide produc-
tion are decreased (Sullivan et al., 2015).
Do Immune Cells and Cancer Cells Compete for
Amino Acids?
While it is clear that all cells need amino acids for protein synthe-
sis and function, the rapid and dramatic changes in immune cell
status have very particular amino acid requirements. Restricting
amino acid supply can compromise immune cell function, a sit-
uation that may arise in a tumorigenic setting to limit anti-tumor
immunity. Cancer cells have a highmetabolic demand and could
compete with immune cells for amino acid resources (Figure 4).
Tumor Cells Have Diverse Amino Acid Requirements
Tumor cells take up amino acids from the external environment
and, like T cells, rely on glutamine uptake (DeBerardinis et al.,
2007). Glycine fuels serine-glycine exchange via Shmt2, and
glycine consumption correlates with cancer cell proliferation
(Jain et al., 2012). Increased Shmt2 activity drives serine meta-
bolism (Yang et al., 2018), which may support cancer cell prolif-
eration by supplying nucleotides. Cancer cells indeed increase
activity of the SGOC network, in which serine is metabolized to
glycine with the concomitant generation of 5, 10-meTHF, a 1-C
donor for nucleotide synthesis (Mehrmohamadi et al., 2014). Tu-
mor-initiating cells have increased methionine cycle activity and
transmethylation rates (Wang et al., 2019b), making these cellsCell Metabolism 32, August 4, 2020 11
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10.1016/j.cmet.2020.06.010dependent on extracellular methionine uptake. Inhibition of
methionine metabolism or limitation of extracellular methionine
enhances cancer cell death. Proline metabolism supports
metastasis formation (Elia et al., 2017), as does pyruvate uptake
by breast cancer cells, which use this metabolite to drive
collagen hydroxylation to remodel the extracellular matrix, facil-
itating metastasis (Elia et al., 2019). This collagen modification
depends on pyruvatemetabolism to aKG,which is accompanied
by alanine secretion, which can drive initial activation of naive
T cells and re-stimulation of Tmem cells (Ron-Harel et al., 2019).
On the other hand, pyruvate can also increase expression of
the immune checkpoint receptor ligand programmed death
ligand (PD-L)1 in macrophages (Watanabe et al., 2017). It would
be intriguing to examine if any of the pyruvate taken up by cancer
cells is used to increase PD-L1 expression and dampen the anti-
tumor response. Increased BCAA catabolism via BCAT1 pro-
motes glioblastoma growth (To¨njes et al., 2013), possibly by
fueling energy-producing metabolic pathways, yet hepatocellu-
lar carcinoma progression is associated with decreased
BCAT1-mediated BCAA catabolism (Ericksen et al., 2019). This
preserves BCAAs to activate mTOR. Thus, it will be important
to delineate the amino acid demands of different cancer types.
Altered amino acid supply in the tumormicroenvironment could
have both pro- and anti-tumor effects, as a result of amino acid
metabolism in both tumor cells and various tumor-associated im-
mune cells. Deprivation of amino acids in Treg cells, for example,
could abolish their suppressive effect onTeff function, thereby pro-
moting anti-cancer activity of Teff cells. TCR stimulation increases
expression of amino acid transporters in Treg cells (Do et al., 2020),
and arginine and leucine promote mTORC1 activity in Treg cells,
via the small G proteins RagA/B and Rheb1/2 (Shi et al., 2019).
This signaling drives suppressive activity of Treg cells, including
inducible T cell costimulator (ICOS) and CTLA4 expression.
RagA deficiency impairs Treg cell proliferation and accumulation
in tumors in a B16 melanoma model, allowing expansion of tu-
mor-infiltrating CD8+ T cells with increased granzyme B levels,
enhancing antitumor immunity (Do et al., 2020). Similarly, different
B cell subtypes can produce immunogenic and immunosuppres-
sive cytokines and thereby exert either pro- or anti-tumor effects,
so amino acid supply to different B cells subsets could either drive
or inhibit anti-tumor responses (Tsou et al., 2016).
It will be important to investigate exactly which cell types take
up amino acids in the tumor microenvironment, and whether
transporter repertoire and copy number vary, giving particular
cells an advantage in terms of amino acid uptake. Glutamate
has differential effects on T cells, dependent on transporter
expression. Gls1 is overexpressed in many cancers, which could
increase glutamate levels. Breast cancer cells secrete glutamate
(Briggs et al., 2016), as do macrophages and DCs (Pacheco
et al., 2007), which often infiltrate tumors. Glutamate inhibits the
xc
 cystine-glutamate antiporter, which could restrict cystine sup-
ply to T cells, decreasing GSH, ROS detoxification, proliferation,
and activation. Naive T cells express the glutamate transporter
mGlu5R, which inhibits TCR-mediated activation and proliferation
(Pacheco et al., 2006), but activated T cells express an alternative
glutamate transporter, mGlu1R, which counters the anti-prolifera-
tive activity of mGlu5R via MEK-ERK1/2 and promotes prolifera-
tion, IL-2, and IFN-g production (Pacheco et al., 2004, 2006).
The balance between these two transporters may determine12 Cell Metabolism 32, August 4, 2020whether glutamate has a pro- or anti-tumor immunity effect. B
cells and DCs also express glutamate receptors, allowing for their
function to be modulated by glutamate. Glutamate signals via the
kainate receptor to increase immunoglobulin production by acti-
vated B cells (Sturgill et al., 2011). Future research will be needed
to provide direct evidence for any competition between tumors
and immune cells for amino acids, and how this may ultimately
modulate protective immunity in cancer.
Tryptophan and Arginine in Anti-Tumor Immunity
Inhibitors of the tryptophan metabolic enzyme indoleamine-2,3-
dioxygenase 1 (IDO-1) have been tested against various types of
cancer, both alone and in combination with checkpoint inhibitors
(Komiya and Huang, 2018). IDO-1 catabolizes tryptophan to ky-
nurenine, and its expression is increased in both cancer cells and
activated immune cells (Yoshida and Hayaishi, 1978), again illus-
trating an overlapping requirement between these cell types.
T cells require tryptophan for proliferation and activation (Lee
et al., 2002; Munn et al., 1999), and using IDO-1 inhibitors to
target cancer cells may dampen T cell-mediated immunity by
limiting tryptophan metabolism, which can induce GCN2
signaling. It is thus crucial to target IDO-1 inhibitors specifically
to cancer cells. Overexpression of IDO in tumor cells can also
impair T cell responses, possibly by driving tryptophan degrada-
tion in cancer cells and limiting tryptophan supply for T cells
(Holmgaard et al., 2013). Increased kynurenine can modulate
T cell responses, inducing apoptosis (Fallarino et al., 2002),
decreasing TCR expression (Fallarino et al., 2006), and promot-
ing Treg cell differentiation (Opitz et al., 2011). Kynurenine may
outcompete the transport of leucine and methionine by Slc7a5/
System L in T cells (Sinclair et al., 2018), possibly pushing a
more regulatory phenotype by limiting leucine and methionine
supply. Kynurenine also inhibits NK cell proliferation (Frumento
et al., 2002) and cytokine production (Della Chiesa et al., 2006).
Tumor-associated pDCs accumulate in tumor-draining lymph
nodes and cause antigen-specific T cell anergy via IDO (Friberg
et al., 2002; Munn et al., 2004). Tumor-associated DCs also
consume arginine and limit its use by T cells, and arginine meta-
bolism to spermidine by DCs further pushes IDO expression
(Mondanelli et al., 2017). This contrasts with the production of
spermidine in T cells, which enhances their anti-tumor effect (Pie-
trocola et al., 2016). Collectively, these actions of DCs limit anti-tu-
mor immunity by T cells. Inhibition of DC arginasemetabolism has
a greater effect on restoring T cell proliferation in a fibrosarcoma
model than restoration of arginine supply alone (Norian et al.,
2009), indicating that it is not just restriction of arginine supply to
T cells that mediates the suppressive effects of DCs. MDSCs
inhibit CD8+ T cell function by targeting intracellular arginine,
rather than arginine uptake. In a recent report, it was shown that
MDSCs transfer the glycine-derived metabolite methylglyoxal to
CD8+ T cells, which forms glycation products with arginine,
thereby depleting free intracellular arginine needed for CD8+
T cell activation (Baumann et al., 2020). Methylglyoxal also op-
poses the increase in glycolysis supporting CD8+ T cell function.
Arginine depletion also dampens IFN-g production and
proliferation of human NK cells (Oberlies et al., 2009).
Tumor-associated macrophages (TAMs) expressing arginase
are associated with pro-tumor growth, whereas TAMs with low
arginase expression drive tumor regression by promoting
macrophage and NK cell-mediated anti-tumor immunity
Figure 5. Amino Acids Support Immune Cell Function by Multiple Mechanisms
While amino acids are known to be used for protein synthesis, they are critical for many other cellular processes. They supply intermediates that drive metabolic
rewiring upon immune cell activation, and are used to make antioxidants such as glutathione, maintaining redox balance. They provide methyl and acetyl groups
to epigenetically modify DNA and histones to facilitate specific gene expression programs in immune cells. These intermediates, and others, can also be used to
post-translationally modify proteins and affect their function. Amino acids drive proliferation and growth by fueling nucleotide synthesis and driving translation,
and can also be stored in lysosomes, driving autophagy as a protective mechanism in times of stress.
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10.1016/j.cmet.2020.06.010(Hagemann et al., 2008). Both direct targeting of intracellular
arginine metabolism by suppressive immune cells and limitation
of extracellular arginine supply limit anti-tumor T cell immunity,
illustrating how immune cells regulate each other via amino
acid metabolism in a tumor setting.
Modulation of Cysteine in Cancer Immunotherapy
Cysteine modulation also controls anti-tumor immunity. Tumor
cells are particularly sensitive to ferroptosis, and CD8+ T cells acti-
vate ferroptosis in tumors in cancer immunotherapy to drive lipid
peroxidation and tumor cell death (Wang et al., 2019a). IFN-g
from these T cells decreases Slc3a2 and Slc7a11, components
of the glutamate-cystine antiporter system xc
, on tumor cells
(Wang et al., 2019a). This limits cystine uptake by tumor cells,
reducing their capacity to antagonize ferroptosis. Cystine and
cysteinedepletion incombinationwithcheckpointblockadesyner-
gistically increase T cell antitumor immunity. MDSCs may limit
T cell activation by restricting cysteine availability to T cells (Srivas-
tava et al., 2010), asmayDCs. This effectmaybe in part due to lim-
itationofGSHsynthesisandalterationof extracellular redoxstatus.
Targeting Amino Acid Metabolism for Anti-Cancer
Treatment
The dependence of cancer cells on amino acid uptake and meta-
bolism implicates the specific targeting of these processes only in
the relevantcell typeasameansofcancer treatment. For example,
a prodrug form of a glutamine antagonist, which is preferentially
activated by enzymes in the tumor microenvironment, decreases
glycolysis and OXPHOS in MC38 colon tumors in vivo, yet pro-
motes these parameters in CD8+ tumor-infiltrating lymphocytes
(TILs) (Leone et al., 2019). TILs, but not MC38 tumor cells, are
able to compensate for decreased glutamine metabolism by
increasingfluxofglycolyticmetabolites into theTCAcycle.Overall,
this enhances antitumor immunity. Recombinant human arginase
1 has been tested in the clinic in an attempt to deplete serum argi-
nine supply to tumor cells (Qiu et al., 2015). In this setting,modula-
tion of arginine supply could also limit anti-tumor T cell activity.
Differential transporter expression on cancer cells and tumor-
associated immune cells may facilitate this specific targeting of
amino acid metabolism. Increased expression of particulartransporters on cancer cells can be used to target drugs specif-
ically to these cells and may also imply an increased reliance of
tumor cells on certain amino acids. For example, cancer cells
frequently increase expression of Slc1a5, Slc38a2, Slc7a5, and
Slc38a5 to increase glutamine uptake, and knockdown or small
molecular targeting of these factors inhibits tumor cell growth in
several different preclinical models (Kandasamy et al., 2018).
Small molecule inhibitors of the system xc
 antiporter compo-
nent Slc7a11, such as sulfasalazine and erastin, may sensitize
tumor cells to oxidative stress (Timmerman et al., 2013). It will
be important to establish selectivity for the transporters of inter-
est, to minimize off-target effects. Amino acid transporters can
also be hijacked to specifically deliver drugs with amino acid
moieties, or amino acid-like structures, to tumor cells. Nitrogen
mustards are a class of DNA alkylating agents that kill tumor
cells. Glycine conjugation to a nitrogen mustard compound al-
lows its uptake by Slc7a5 and selective killing of cancer cells
with high Slc7a5 expression (Hosoya et al., 2008).
Cancers exposed to high oxidative stress use amino acids to
produce antioxidant molecules. Lung adenocarcinomas with nu-
clear factor erythroid 2-related factor (Nrf)2/ Kelch-like ECH-
associated protein (Keap)1 mutations are highly dependent on
exogenous non-essential amino acids, and diets lacking aspar-
agine or both serine and glycine reduce Keap1 mutant tumor
growth in mice (LeBoeuf et al., 2020). This implicates dietary in-
terventions as potential anti-cancer strategies. Acutemethionine
restriction sensitizes tumor cells to chemotherapy and radiation
treatment in mouse colorectal cancer and sarcoma models, and
such acute methionine limitation was tolerated in mouse and a
small human sample (Gao et al., 2019).
Open Questions and Future Directions
Amino acids influence immune cell function in many more ways
beyond providing material for protein synthesis. Their roles in
central energy metabolism, redox balance, epigenetic modifica-
tion, and PTMs allow them to modulate immunity via multiple
mechanisms (Figure 5) and, consequently, provide a variety of
targets for therapeutic intervention (Box 2).Cell Metabolism 32, August 4, 2020 13
Box 2. Therapeutic Implications of Targeting Amino Acid Metabolism
d Amino acid metabolism can be targeted at multiple points, by altering dietary supply, or by modulating transporters, metabolic
enzymes, or storage.
d Inhibitors of the transporters Slc7a5 (Geier et al., 2013) and Slc1a5 (Schulte et al., 2018) antagonize cancer cell growth. This
could spare amino acids to boost immune cell function in a tumor microenvironment, a phenomenon that occurs when gluta-
mine metabolism is specifically blocked in cancer cells (Leone et al., 2019). Transporter inhibition could also target immune
cells to dampen autoimmunity or hyperinflammation.
d Erastin and sulfasalazine inhibit the cystine-glutamate antiporter, which could limit T cell activation in EAE (Evonuk et al., 2015).
d Multiple compounds, including BPTES and CB-839, inhibit glutamine metabolizing enzymes, with potential benefits in EAE
(Kono et al., 2018) and rheumatoid arthritis (Takahashi et al., 2017).
d Blocking GSH synthesis with buthionine sulfoximine could spare its component amino acids for tRNA thiolation and increased
biosynthesis, possibly promoting immune cell proliferation and activation.
d Serine limitation dampens excessive macrophage activation in endotoxemia (Rodriguez et al., 2019), which may aid sepsis
treatment.
d Halofuginone mimics amino acid starvation by pharmacologically activating GCN2. This compound reduces gut inflammation
(Ravindran et al., 2016) and induces autophagy (Chen et al., 2017), which may increase longevity by opposing the age-related
decline in immune cell function.
d Modulating amino acid supply to tumors in combination with checkpoint blockade is a promising anti-cancer strategy, as
observed for cysteine/cystine depletion in a melanoma model (Wang et al., 2019a).
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manipulate amino acid metabolism, so much so that viruses
have evolved to target amino acid transporters. HIV targets serine
incorporators 3 and 5, and SNAT1 (Slc38a1), on T cells to restrict
T cell mitogenesis and antiviral immunity (Matheson et al., 2015).
In this respect, amino acid transporters are good possible drug
targets, and dietary interventions could have similar effects.
Both strategiesmay bebeneficial to treat cancer and other pathol-
ogies (Box 2). Dietary interventions may avoid undesirable side
effects associated with pharmacological treatments. Dietary
methionine restriction limits autoimmunity, decreasing Th cell acti-
vation and consequently delaying EAE onset and progression
(Roy et al., 2020). This work clearly illustrates that limitation of
just one nutrient can delay disease. Conversely, amino acid sup-
plementation could boost anti-pathogen immunity. In particular, a
number of clinical trials have been conducted with arginine
supplementation, which enhances NK cell activity and antibody
production in an older population vaccinated against Strepto-
coccus pneumoniae (Moriguti et al., 2005).
The relevance ofmany novel amino acidmetabolic pathways to
immune cells is as yet unknown. Diverse immune cells are likely to
respond differently to amino acid perturbations, depending on
whether they express transporters and intracellular metabolic en-
zymes to process these amino acids. Amino acids outside the
proteinogenic 20 remain to be examined. For example, taurine
metabolism is modulated by LPS and IFN-g, and its transporter
is regulated in fetal T cells (Iruloh et al., 2007). Selenocysteine is
an excellent antioxidant and occurs in enzymes including gluta-
thione peroxidases. Selenoprotein deficiency reduces the number
of mature T cells emerging from lymphoid tissues, decreases
TCR-induced calcium flux (Verma et al., 2011), and antagonizes
T cell proliferation due to decreased buffering of ROS (Shrimali
et al., 2008), and roles for selenoproteins have been proposed in
allergic airway inflammation (Hoffmann et al., 2007).
Different tissues and niches contain different amino acid
repertoires (Behringer et al., 2019), a concept that is particu-14 Cell Metabolism 32, August 4, 2020larly relevant to migratory immune cells, which are likely to
experience various microenvironments. Immune cells may
elect not to indiscriminately use available amino acids for pro-
tein synthesis, but to selectively use them or store them. Lyso-
somes could release stored amino acids according to demand
or limit them to induce autophagy as a protective mechanism
when nutrients are scarce. Amino acids could also be stored
in the form of small peptides such as glutathione, which could
then be catabolized to release cysteine, glutamate, and
glycine, which can in turn be metabolized to other amino
acids. The intracellular amino acid pool is also regulated by
transporter expression, but many amino acid transporters
remain unidentified.
Amino acid-derived PTMs have been investigated in bacte-
ria, including lysinylation (Kristian et al., 2003) and alanylation
(Saar-Dover et al., 2012), while arginylation prevents neurode-
generation in mice (Wang et al., 2017a). However, many
PTMs have not been investigated in an immune cell, or even
a mammalian, context. Amino acid supply may dictate the
type of PTM formed. For example, the autophagy inhibitor
EP300 can be activated by acetylation or inhibited by spermi-
dine. BCAAs provide acetyl groups by generating acetyl-CoA,
while arginine provides spermidine. It would be intriguing to
investigate whether the balance between BCAAs and arginine
influences which modification dominates, or if such a phenom-
enon occurs for other PTMs.
Overall, targeting immune cell amino acid metabolism is a
useful means of augmenting or antagonizing immune re-
sponses, and increased understanding of amino acid meta-
bolism in immune cells is likely to be of great therapeu-
tic benefit.ACKNOWLEDGMENTS
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